GlassScriptPhysician profile
Craig S Self
NPI 1154301844
$1,828.72
in general payments reported to CMS, 2019-2025
22 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $37.35 · 2021: $370 · 2022: $286 · 2023: $37.39 · 2024: $195 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $783.01 | 2019-2025 | Clareon, Simbrinza |
| Carl Zeiss Meditec, INC. | $165.71 | 2021 | |
| Allergan, INC. | $157.02 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $131.13 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $92.34 | 2024 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $66.68 | 2019-2022 | |
| Harrow Eye, LLC | $64.42 | 2025 | Iheezo |
| Amgen INC. | $45.74 | 2024-2025 | Tepezza |
| Abbvie INC. | $45.34 | 2023-2024 | Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $38.95 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.67 | 2019 | |
| Ani Pharmaceuticals, INC. | $29.98 | 2025 | Iluvien |
| Dompe US, INC. | $24.72 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $23.35 | 2024 | Eylea Hd |
| Biotissue Holdings INC. | $19.22 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $18.90 | 2022 | |
| Kala Pharmaceuticals, INC. | $18.12 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.70 | 2025 | Syfovre |
| Ocular Therapeutix, INC. | $14.35 | 2020 | |
| Rayner Intraocular Lenses Limited | $13.63 | 2025 | Omidria |
| Eyepoint US, INC. | $12.63 | 2019 | |
| Omeros Corporation | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.